FLAME 30
Liver Disease Treatments: The Global Market
Report Highlights
In 2009, the global market for drugs used to treat liver disease was worth approximately $12.4 billion. Sales in 2010 decreased and the market did not see much progress, causing overall global sales to remain stagnant at $12.4 billion. Estimated sales in 2011 a projected $12 billion (excluding protease inhibitors). The market is expected to rise at a CAGR of 3.3% and reach nearly $14.2 billion by 2016.
SCOPE OF THE STUDY
The scope of this study encompasses liver disease drug markets by various types. BCC Research analyzes each market by category with its applications in different regions of the world. It also analyzes the market leaders, regulatory environment, technology, market projections, and market share. Application issues include the latest trends and developments in each liver disease drug category.
Analyst Credentials
Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.
- Global Markets for CT Scanners (HLC024B)
- Technologies for Long-term Care and Home Healthcare: Global Markets (HLC079D)
- Renal Dialysis Equipment: Technologies and Global Markets (HLC164B)
- Fluoroscopy and C-arms: Technologies and Global Markets (HLC148B)
- Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging (PHM043G)
Report Highlights
- The global market for liver disease treatments amounted to nearly $8.4 billion in 2007 and is expected to increase to $9.8 billion in 2014, for a compound annual growth rate (CAGR) of 3.0%
- The treatment for hepatitis is the largest segment of the market, amounting to about $4.6 billion in the last three years, and is expected to reach $4.8 billion in 2014.
- Sales of targeted therapies were comparatively less in 2008, but this market has the potential to grow faster mainly because of the increased incidence of hepatitis C in developing countries.
